Phase 3 Remdesivir Data Shows Uncertain Benefits in Moderately Ill COVID-19 Patients

New data from Gilead Sciences’ late-stage trial of its antiviral remdesivir show that a five-day course of the drug helped patients with moderate COVID-19 pneumonia, but the finding was of “uncertain clinical importance,” according to researchers.

Patients enrolled in the 600-participant trial had a better chance of improvement compared to those on standard care, but the clinical significance of the benefit wasn’t clear, according to findings published in the Journal of the American Medical Association.

Remdesivir is the only drug so far to receive an Emergency Use Authorization from the FDA for treating COVID-19.